🇺🇸 FDA
Patent

US 9700562

Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis

granted A61KA61K31/53A61K31/5377

Quick answer

US patent 9700562 (Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis) held by The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
Grant date
Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/53, A61K31/5377, A61K45/06, A61P